<p>The purpose of this study is to (1) compare a technically improved assay with an existing assay used to measure serum anti-GM-CSF antibodies in stored serum samples previously obtained from patients diagnosed with either primary, secondary, congenital or idiopathic pulmonary alveolar proteinosis (PAP), other chronic diseases or disease-free, healthy individuals; (2) determine the prevalence and levels of anti-GM-CSF autoantibodies and (3) define the breadth of the autoimmune antibody responses in primary PAP patients from the United States, Japan, Australia, and Europe using previously collected serum samples; and (4) using a chart review approach, compare the clinical, radiologic and laboratory features of primary PAP patients to determine if differences exist among patients in these globally geographically distributed regions.</p>

MICEPAP Trial

384 variables across Anthropometry, Biomarkers, Demographics + 9 more

MICEPAP Trial

Anthropometry (10)

Biomarkers (18)

Demographics (14)

Disease Events (59)

Environment (3)

General Health (6)

Imaging (5)

Medications (1)

Race and Ethnicity (7)

Respiratory (30)

Socioeconomic (1)

Substance Use (7)

Other (223)